Yale University: Psychotic Disorders trials

The registry lists 27 Psychotic Disorders studies with Yale University as lead sponsor. 0 are open to participants now and 9 have results posted.

Early Phase 1 5Phase 1 5Phase 2 3Phase 3 2No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Models of Auditory HallucinationTerminatedNCT04210557Not applicableResults posted
• Cannabidiol Treatment in Patients With Early PsychosisCompletedNCT02504151Phase 2Results posted
• Naltrexone for Antipsychotic-Induced Weight GainCompletedNCT01866098Not applicableResults posted
• Pilot Trial of Naltrexone for Obesity in Women With SchizophreniaCompletedNCT00793780Not applicableResults posted
• Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With SchizophreniaCompletedNCT00645944Not applicableResults posted
• Ziprasidone in the Psychosis ProdromeCompletedNCT00635700Phase 2Results posted
• Cannabidiol Treatment of Cognitive Dysfunction in SchizophreniaCompletedNCT00588731Phase 2Results posted
• Specialized Treatment Early in Psychosis (STEP)CompletedNCT00309452Not applicableResults posted
• D-Serine Treatment of Negative Symptoms and Cognitive Deficits in SchizophreniaCompletedNCT00237809Phase 3Results posted
• An Intervention to Correct Dualistic Reasoning About the Effectiveness of Psychotherapy for Biologically Caused Mental DisordersCompletedNCT05800119Not applicable
• M1 Schizophrenia PET StudyCompletedNCT05105542Phase 1
• Psychodynamic Psychotherapy for PsychosisWithdrawnNCT04415541Not applicable
• BXCL501 for Agitation in SchizophreniaCompletedNCT03708315Phase 1
• A Pilot Trial of Curcumin Effects on Cognition in SchizophreniaTerminatedNCT02476708Not applicable
• Cannabinoids, Learning, and MemoryActive, not recruitingNCT02407808Phase 1
• Probing the Cannabinoid System in Individuals With a Family History of PsychosisActive, not recruitingNCT02102113Early Phase 1
• STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.CompletedNCT02069925Not applicable
• Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosisTerminatedNCT02047539Early Phase 1
• Cannabinoids and Cerebellar-Motor FunctioningCompletedNCT01853020Early Phase 1
• Social Cognitive Training for Psychosis: Treatment DevelopmentCompletedNCT01579422Phase 1
• Lifestyle Modification for Weight Loss in SchizophreniaCompletedNCT00990925Not applicable
• Effects of Delta-9-THC and Iomazenil in Healthy HumansCompletedNCT00982982Early Phase 1
• Cannabinoids, Neural Synchrony, and Information ProcessingCompletedNCT00708994Early Phase 1
• Recovery Guide Intervention for Recurrent Psychiatric HospitalizationCompletedNCT00400166Not applicable
• Enhancing the Prospective Prediction of PsychosisCompletedNCT00291200
• D-Serine for Enhancing Cognitive Retraining for the Treatment of SchizophreniaCompletedNCT00237848Phase 3
• Culturally Responsive Person-Centered Care for PsychosisCompletedNCT00231933Phase 1